GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has a commercial presence in approximately 150 markets in 36 countries and research and development centres in the U.K., USA, Belgium and China. Businesses The company operates in three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. Pharmaceuticals The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The company offers a portfolio of products, such as Seretide/Advair, Ventolin and Flovent. It also offers medicines, such as Relvar/Breo Ellipta, an inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA) combination; Anoro Ellipta, a long-acting muscarinic antagonist (LAMA) and LABA dual bronchodilator; and Incruse Ellipta (LAMA) and Arnuity Ellipta (ICS). The company has other respiratory products in its pipeline, including mepolizumab, an investigational anti-IL5 monoclonal antibody, to treat severe eosinophilic asthma, and its ‘closed’ triple combination treatment to treat chronic obstructive pulmonary disease. The company’s HIV business is managed through ViiV Healthcare, a specialist company in HIV that the company majority owns, with Pfizer and Shionogi as the other shareholders. The company has a portfolio of other Pharmaceutical products for the treatment of conditions, such as lupus (Benlysta), benign prostatic hyperplasia (Avodart/Jalyn), type 2 diabetes (the company launched Tanzeum/ Eperzan) and bacterial infections (Augmentin). The company has had multiple regulatory approvals and product launches, including Tykerb/Tyverb, Votrient, Promacta/Revolade, Arzerra, Tafinlar and Mekinist. In addition, the company has an Established Products Portfolio (EPP) which includes approximately 50 off-patent products, as well as its branded generics business and other local products. Vaccines The Vaccines business has a portfolio of approximately 30 paediatric, adolescent, adult and travel Vaccines. The company’s four major vaccines by sales are Infanrix (diphtheria and tetanus), Hepatitis, Rotarix (rotavirus) and Synflorix (pneumonia). The company is also one of the contributors to Gavi, the Vaccine Alliance, a public-private partnership to improve access to vaccines in developing countries. Consumer Healthcare The Consumer Healthcare business products reach people in approximately 100 countries, with its brands, including Sensodyne, Panadol and Horlicks. Its four categories include Wellness, Oral health, Nutrition, and Skin health. The company’s Wellness category focuses on pain management, respiratory health, gastrointestinal health and smokers’ health. Panadol is the paracetamol brand and Tums is the antacid brand in the USA. The company offers products in specialist Oral health, with positions in sensitivity (Sensodyne), acid erosion (Pronamel), denture care, and gum health. In Nutrition, the company offers Horlicks brand, a nutritional supplement in the Indian subcontinent. Its Skin health brands include Abreva and Zovirax. Research and Development In 2014, the company spent £3.1 billion before non-core items to develop innovative medicines, vaccines and consumer products. Competition The company’s principal research-based pharmaceutical and vaccines competitors include AbbVie, Amgen, Astra Zeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, Novo Nordisk, Pfizer, Roche Holdings, Sanofi and Takeda. The company’s consumer healthcare competitors include Colgate-Palmolive, Johnson & Johnson, Procter & Gamble, Reckitt Benckiser, and Novartis. Significant Events In March 2014, Cold Spring Harbor Laboratory (CSHL) announced a collaboration with GSK to develop a treatment for obesity and type 2 diabetes. In April 2015, ADRs of GlaxoSmithKline plc announced that it will establish a new global center for vaccines research and development in Rockville, Maryland. In April 2015, The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute announced they are collaborating with GlaxoSmithKline (GSK) on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. In May 2015, The University of North Carolina at Chapel Hill and GSK announced the creation of the dedicated HIV Cure center and a jointly owned new company that would focus on discovering a cure for HIV/AIDS. In June 2015, GlaxoSmithKline (UK) has announced the launch of an independent non-profit research institute - the Altius Institute for Biomedical Sciences - based in Seattle, Washington. GSK signed a 10-year research agreement with Altius, whereby the firm would contribute more than USD 95 million in the first five years to help fund research activities that are also anticipated to receive funding from public and other sources. In July 2015, Medical Research Council (MRC) and GlaxoSmithKline (GSK) and five leading UK universities collaborate to crack difficult disease areas. MRC and GSK are to collaborate on a unique open innovation research initiative aiming to improve scientists' understanding of inflammatory diseases that present a serious burden to patients. History GlaxoSmithKline plc was founded in 1935.
glaxosmithkline plc-spon adr
980 Great West Road
Brentford, TW8 9GS
Phone: 44 20 8047 5000
|AbbVie Inc||$60.98 USD||+0.48|
|Bristol-Myers Squibb Co||$59.61 USD||+1.41|
|Celgene Corp||$119.58 USD||+4.12|
|Eli Lilly & Co||$81.81 USD||+2.01|
|Medtronic PLC||$71.55 USD||+2.02|
|View Industry Companies|
Sponsored Financial Commentaries
To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.